Compare AMKR & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMKR | JAZZ |
|---|---|---|
| Founded | 1968 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 10.4B |
| IPO Year | 1998 | 2007 |
| Metric | AMKR | JAZZ |
|---|---|---|
| Price | $51.29 | $164.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 16 |
| Target Price | $42.00 | ★ $207.19 |
| AVG Volume (30 Days) | ★ 4.2M | 1.1M |
| Earning Date | 02-09-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $6,449,053,000.00 | $4,157,832,999.00 |
| Revenue This Year | $7.49 | $6.00 |
| Revenue Next Year | $9.04 | $6.35 |
| P/E Ratio | $40.92 | ★ N/A |
| Revenue Growth | 0.14 | ★ 4.14 |
| 52 Week Low | $14.03 | $95.49 |
| 52 Week High | $55.17 | $182.99 |
| Indicator | AMKR | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 59.41 | 46.14 |
| Support Level | $49.00 | $164.40 |
| Resistance Level | $55.17 | $171.70 |
| Average True Range (ATR) | 3.05 | 5.60 |
| MACD | -0.27 | -0.42 |
| Stochastic Oscillator | 55.47 | 48.61 |
Amkor Technology Inc is a OSAT (outsourced semiconductor assembly and test) service provider. It has pioneered the outsourcing of integrated circuit (IC) packaging and test services and is a strategic manufacturing partner for the semiconductor companies, foundries, and electronics original equipment manufacturers (OEMs). The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.